Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | NSCLC | Research

Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutation: an ambispective cohort study

Authors: Xingxiang Pu, Yu Zhou, Yi Kong, Bolin Chen, Aifang Yang, Jia Li, Kang Li, Yan Xu, Lin Wu

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Background

About 10% of non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations are harbored as uncommon mutations. This study aimed to explore the efficacy and safety of dacomitinib, a second-generation EGFR tyrosine kinase inhibitor (EGFR-TKIs), in treating uncommon EGFR-mutated advanced NSCLC.

Methods

Treatment-naïve advanced NSCLC patients treated with dacomitinib at Hunan Cancer Hospital with uncommon EGFR mutations were evaluated. The primary endpoint was progression-free survival (PFS). Secondary end points included overall survival (OS), objective response rate (ORR), disease control rate (DCR) and safety.

Result

Between December 2019 and December 2021, a total of 16 patients was included. Median PFS was 14.0 (95% CI 4.32–23.7) months, and median OS was not reached. ORR was 68.8% (95% CI 41.3 to 89.0%) and DCR was 93.8% (95%CI 69.8 to 99.8%), including three achieving complete remission (CR) and eight achieving partial remission (PR). Median PFS for patients with brain metastasis was 9.0 (95%CI 6.9 to 11.1) months. Intracranial ORR was 100%, including 2 CR and 4 PR. Major treatment-related adverse events (TRAEs) included rash (87.5%), paronychia (62.5%), oral ulcers (50.0%), and diarrhea (50.0%), none of which were ≥ grade 3 TRAEs.

Conclusions

Dacomitinib showed good activity and manageable toxicity in NSCLC patients with uncommon EGFR mutations.
Appendix
Available only for authorised users
Literature
1.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49.CrossRefPubMed
2.
Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WEE, et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2016;11(1):39–51.CrossRefPubMed
3.
Passaro A, Mok T, Peters S, Popat S, Ahn M-J, de Marinis F. Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions. EGFR Mutations J Thorac Oncol. 2021;16(5):764–73.CrossRefPubMed
4.
Chan BA, Hughes BG. Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. Transl Lung Cancer Res. 2015;4(1):36–54.PubMedPubMedCentral
5.
Leduc C, Merlio JP, Besse B, Blons H, Debieuvre D, Bringuier PP, et al. Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program. Ann Oncol. 2017;28(11):2715–24.CrossRefPubMed
6.
Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2018;378(2):113–25.CrossRefPubMed
7.
Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18(11):1454–66.CrossRefPubMed
8.
Wu S-G, Yu C-J, Yang JC-H, Shih J-Y. The effectiveness of afatinib in patients with lung adenocarcinoma harboring complex epidermal growth factor receptor mutation. Ther Adv Med Oncol. 2020;12:1758835920946156.
9.
Gristina V, Malapelle U, Galvano A, Pisapia P, Pepe F, Rolfo C, et al. The significance of epidermal growth factor receptor uncommon mutations in non-small cell lung cancer: A systematic review and critical appraisal. Cancer Treat Rev. 2020;85: 101994.CrossRefPubMed
10.
Yang JC, Schuler M, Popat S, Miura S, Heeke S, Park K, et al. Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases. J Thorac Oncol. 2020;15(5):803–15.CrossRefPubMed
11.
Jänne PA, Boss DS, Camidge DR, Britten CD, Engelman JA, Garon EB, et al. Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors. Clin Cancer Res. 2011;17(5):1131–9.CrossRefPubMedPubMedCentral
12.
Reckamp KL, Giaccone G, Camidge DR, Gadgeel SM, Khuri FR, Engelman JA, et al. A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib. Cancer. 2014;120(8):1145–54.CrossRefPubMed
13.
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.
14.
Wu J-Y, Yu C-J, Chang Y-C, Yang C-H, Shih J-Y, Yang P-C. Effectiveness of tyrosine kinase inhibitors on “uncommon” epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. Clin Cancer Res. 2011;17(11):3812–21.
15.
Watanabe S, Minegishi Y, Yoshizawa H, Maemondo M, Inoue A, Sugawara S, et al. Effectiveness of gefitinib against non-small-cell lung cancer with the uncommon EGFR mutations G719X and L861Q. J Thorac Oncol. 2014;9(2):189–94.CrossRefPubMedPubMedCentral
16.
Baek JH, Sun J-M, Min YJ, Cho EK, Cho BC, Kim J-H, et al. Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small cell lung cancer except both exon 19 deletion and exon 21 L858R: a retrospective analysis in Korea. Lung Cancer. 2015;87(2):148–54.CrossRefPubMed
17.
Chiu C-H, Yang C-T, Shih J-Y, Huang M-S, Su W-C, Lai R-S, et al. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations. J Thorac Oncol. 2015;10(5):793–9.CrossRefPubMed
18.
Kuiper JL, Hashemi SMS, Thunnissen E, Snijders PJF, Grünberg K, Bloemena E, et al. Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment. Br J Cancer. 2016;115(12):1504–12.CrossRefPubMedPubMedCentral
19.
Krawczyk P, Kowalski DM, Ramlau R, Kalinka-Warzocha E, Winiarczyk K, Stencel K, et al. Comparison of the effectiveness of erlotinib, gefitinib, and afatinib for treatment of non-small cell lung cancer in patients with common and rare gene mutations. Oncol Lett. 2017;13(6):4433–44.CrossRefPubMedPubMedCentral
20.
Pilotto S, Rossi A, Vavalà T, Follador A, Tiseo M, Galetta D, et al. Outcomes of first-generation EGFR-TKIs against non-small-cell lung cancer harboring uncommon EGFR mutations: a post Hoc analysis of the BE-POSITIVE study. Clin Lung Cancer. 2018;19(1):93–104.
21.
Wang C, Zhao K, Hu S, Dong W, Gong Y, Li M, et al. Clinical outcomes of gefitinib and erlotinib in patients with NSCLC harboring uncommon EGFR mutations: A pooled analysis of 438 patients. Lung cancer (Amsterdam, Netherlands). 2022;172:86–93.CrossRefPubMed
22.
Yang JCH, Sequist LV, Geater SL, Tsai C-M, Mok TSK, Schuler M, et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol. 2015;16(7):830–8.CrossRefPubMed
23.
Guardiola S, Varese M, Sánchez-Navarro M, Giralt E. A Third Shot at EGFR: New Opportunities in Cancer Therapy. Trends Pharmacol Sci. 2019;40(12):941–55.CrossRefPubMed
24.
Li HS, Yang GJ, Cai Y, Li JL, Xu HY, Zhang T, et al. Dacomitinib for Advanced Non-small Cell Lung Cancer Patients Harboring Major Uncommon EGFR Alterations: A Dual-Center, Single-Arm, Ambispective Cohort Study in China. Front Pharmacol. 2022;13: 919652.CrossRefPubMedPubMedCentral
25.
Cho JH, Lim SH, An HJ, Kim KH, Park KU, Kang EJ, et al. Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09). J Clin Oncol. 2020;38(5):488–95.CrossRefPubMed
26.
Bar J, Peled N, Schokrpur S, Wolner M, Rotem O, Girard N, et al. UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-LiNe Setting (UNICORN). J Thorac Oncol. 2023;18(2):169–80.CrossRefPubMed
27.
Preusser M, Winkler F, Valiente M, Manegold C, Moyal E, Widhalm G, et al. Recent advances in the biology and treatment of brain metastases of non-small cell lung cancer: summary of a multidisciplinary roundtable discussion. ESMO open. 2018;3(1): e000262.CrossRefPubMedPubMedCentral
28.
Shan C-G, Wang H, Lin T, Liu D, Wen L, Chen Z-J, et al. A non-small cell lung cancer (NSCLC) patient with leptomeningeal metastasis harboring rare epidermal growth factor receptor (EGFR) mutations G719S and L861Q benefited from doubling dosage of osimertinib: a case report. Ann Palliat Med. 2021;10(5):5897–901.CrossRefPubMed
29.
Ma C, Zhang J, Tang D, Ye X, Li J, Mu N, et al. Tyrosine Kinase Inhibitors Could Be Effective Against Non-small Cell Lung Cancer Brain Metastases Harboring Uncommon EGFR Mutations. Front Oncol. 2020;10:224.CrossRefPubMedPubMedCentral
30.
Peng W, Pu X, Jiang M, Wang J, Li J, Li K, et al. Dacomitinib induces objective responses in metastatic brain lesions of patients with EGFR-mutant non-small-cell lung cancer: A brief report. Lung Cancer. 2021;152:66–70.CrossRefPubMed
31.
Zhang J, Wang Y, Liu Z, Wang L, Yao Y, Liu Y, et al. Efficacy of dacomitinib in patients with EGFR-mutated NSCLC and brain metastases. Thorac Cancer. 2021;12(24):3407–15.CrossRefPubMedPubMedCentral
32.
Mizusaki S, Otsubo K, Ninomiya T, Arimura H, Tsuchiya-Kawano Y, Inoue K. Remarkable response to dacomitinib in a patient with leptomeningeal carcinomatosis due to EGFR-mutant non-small cell lung cancer. Thorac Cancer. 2021;12(1):114–6.CrossRefPubMed
33.
Kudo K, Kawakado K, Kawajiri T, Nishi T, Makimoto G, Tamura T, et al. Dramatic Response of Brain Metastasis from EGFR-mutation-positive NSCLC to Dacomitinib. Intern Med. 2020;59(14):1739–40.CrossRefPubMedPubMedCentral
34.
Li H-S, Yang G-J, Cai Y, Li J-L, Xu H-Y, Zhang T, et al. Dacomitinib for Advanced Non-small Cell Lung Cancer Patients Harboring Major Uncommon EGFR Alterations: A Dual-Center, Single-Arm, Ambispective Cohort Study in China. Front Pharmacol. 2022;13: 919652.CrossRefPubMedPubMedCentral
35.
Brindel A, Althakfi W, Barritault M, Watkin E, Maury JM, Bringuier PP, et al. Uncommon EGFR mutations in lung adenocarcinoma: features and response to tyrosine kinase inhibitors. J Thorac Dis. 2020;12(9):4643–50.CrossRefPubMedPubMedCentral
Metadata
Title
Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutation: an ambispective cohort study
Authors
Xingxiang Pu
Yu Zhou
Yi Kong
Bolin Chen
Aifang Yang
Jia Li
Kang Li
Yan Xu
Lin Wu
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-11465-2

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue

Retraction Note

Retraction Note: Invasion inhibition in pancreatic cancer using the oral iron chelating agent deferasirox

Research

Screening of prognosis-related Immune cells and prognostic predictors in Colorectal Cancer Patients

Research

A differential diagnosis between uterine leiomyoma and leiomyosarcoma using transcriptome analysis

Research

Construction of a comprehensive predictive model for axillary lymph node metastasis in breast cancer: a retrospective study

Research

Comparison of clinical outcomes among cancer patients treated in and out of clinical trials

Research

Biomarker analysis for patients with pancreatic cancer treated with nanoliposomal irinotecan plus 5-fluorouracil/leucovorin

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits